Pulse Biosciences (PLSE) awards CTO 100,000 Restricted Stock Units

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

UECKER DARRIN reported acquisition or exercise transactions in this Form 4 filing.

PULSE BIOSCIENCES, INC. reported that Chief Technology Officer Darrin Uecker received a grant of 100,000 Restricted Stock Units. Each RSU represents a contingent right to receive one share of common stock. Following this grant, he holds 100,000 RSUs.

The RSUs are scheduled to fully vest on March 23, 2029, the three-year anniversary of the grant, provided he continues to serve with the company through that date. This is a stock-based compensation award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider UECKER DARRIN

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	100,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 100,000 shares (Direct)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock. The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date.

Key Figures

RSUs granted: 100,000 units Shares underlying RSUs: 100,000 shares Exercise/Conversion price: $0.00 per share +2 more

5 metrics

RSUs granted 100,000 units Restricted Stock Units awarded to CTO on March 23, 2026

Shares underlying RSUs 100,000 shares Common stock underlying granted RSUs

Exercise/Conversion price $0.00 per share RSUs granted at no cash exercise price

Vesting date March 23, 2029 Full vesting date, subject to continued service

Total derivative holdings after grant 100,000 RSUs Total RSUs held following this Form 4 transaction

Key Terms

Restricted Stock Units, contingent right, vest, continued service

4 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of Issuer's common stock"

vest financial

"The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"subject to the Reporting Person's continued service through to that date"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 05:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

UECKER DARRIN

(Last)

(First)

(Middle)

C/O PULSE BIOSCIENCES, INC.

3957 POINT EDEN WAY

(Street)

HAYWARD

CALIFORNIA

94545

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/23/2026		A		100,000		03/23/2029⁽²⁾	03/23/2029⁽²⁾	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.

2. The RSUs will fully vest on March 23, 2029, the three-year anniversary of the grant, subject to the Reporting Person's continued service through to that date.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PLSE disclose for Darrin Uecker?

PULSE BIOSCIENCES, INC. disclosed that Chief Technology Officer Darrin Uecker received 100,000 Restricted Stock Units as a compensation award. These RSUs provide a contingent right to receive an equal number of common shares if vesting conditions are met.

How many Restricted Stock Units were granted to the PLSE CTO?

The Chief Technology Officer of PULSE BIOSCIENCES, INC. was granted 100,000 Restricted Stock Units. Each RSU corresponds to one share of common stock, giving him a potential future claim on 100,000 shares if vesting requirements are satisfied.

When do Darrin Uecker’s PLSE RSUs vest?

The 100,000 Restricted Stock Units granted to Darrin Uecker will fully vest on March 23, 2029. Vesting is contingent on his continued service with PULSE BIOSCIENCES, INC. through that date, meaning he must remain with the company to receive the shares.

Is the PLSE Form 4 transaction a market purchase or sale?

The PLSE Form 4 does not show a market purchase or sale; it records a grant of 100,000 Restricted Stock Units to the CTO. This is stock-based compensation with no cash paid per share and no open-market trading activity reported in this transaction.

What does each PLSE Restricted Stock Unit represent?

Each PULSE BIOSCIENCES, INC. Restricted Stock Unit represents a contingent right to receive one share of the company’s common stock. The units convert into actual shares only if vesting conditions, including continued service through March 23, 2029, are fully met.